BNP PARIBAS ARBITRAGE/PUT/BIONTECH ADR/110/0.1/20.12.24 Share Price

Warrant

P20T09

NLBNPIT20T09

Market Closed - Borsa Italiana 01:34:59 29/06/2024 am IST
2.66 EUR -0.19% Intraday chart for BNP PARIBAS ARBITRAGE/PUT/BIONTECH ADR/110/0.1/20.12.24
Current month+85.00%
1 month+51.72%
Date Price Change
28/24/28 2.64 -0.94%
27/24/27 2.665 +6.39%
26/24/26 2.505 +5.47%
25/24/25 2.375 +6.98%
24/24/24 2.22 -6.53%

Real-time Borsa Italiana

Last update June 29, 2024 at 01:34 am IST

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying BIONTECH SE
IssuerLogo Issuer BNP Paribas BNP Paribas
P20T09
ISINNLBNPIT20T09
Date issued 18/03/2024
Strike 110 $
Maturity 20/12/2024 (173 Days)
Parity 10 : 1
Emission price-
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.73
Lowest since issue 1.253
Delta-0.83x
Omega 2.335
Premium-1.36x
Gearing2.82x
Moneyness 1.369
Difference Strike 29.64 $
Difference Strike %+26.95%
Spread 0.12
Spread %4.40%
Theoretical value 2.665
Implied Volatility 38.34 %
Total Loss Probability 11.18 %
Intrinsic value 2.767
Present value -0.102377
Break even 81.46 €
Theta-0x
Vega0.01x
Rho-0.03x

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
75 EUR
Average target price
103.5 EUR
Spread / Average Target
+38.03%
Consensus
  1. Stock Market
  2. Warrants
  3. P20T09 Warrant